跳至主要内容
临床试验/NCT05576168
NCT05576168已完成不适用

Shanghai Tenth People's Hospital,School of Medicine,Tongji University

Shanghai 10th People's Hospital1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2018年5月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
200
试验地点
1
主要终点
RBP4

研究概览

简要总结

Retinol binding protein 4 ( RBP4 ) is a newly discovered adipokine secreted by adipose tissue, which leads to insulin resistance ( IR ) and participates in the occurrence of T2DM. At present, it's not clear whether RBP4 can cause islet β cell dysfunction. The purpose of this study is to explore the role of serum apo-RBP4 in the pathogenesis of newly diagnosed T2DM patients.

详细描述

In recent years, with the improvement of living standards and lifestyle changes, the incidence of type II diabetes is increasing, and T2DM has become a worldwide disease that seriously endangers people ' s health. When patients with diabetes in the middle and late, the condition is often irreversible, and early if effective treatment, help to improve the condition in a timely manner, delay the development of the disease process. Therefore, early diagnosis and treatment is the key to prevention and treatment of diabetes. Years of studies have shown that insulin resistance and β-cell dysfunction are the two major mechanisms of type II diabetes. Previous studies on the pathogenesis of type II diabetes mostly focused on insulin resistance, and there are few studies on β-cell dysfunction. Therefore, the study of islet β-cell dysfunction is extremely important. According to previous studies, the investigator found that although insulin resistance exists in type II diabetes, also exists to the same extent in many people who do not have diabetes. These people may have or do not have metabolic syndrome. Therefore, insulin resistance alone cannot be the decisive pathogenic factor of type II diabetes, and the increasing facts indicate that the abnormality of islet cells, especially islet β cells, may be the central link in the pathogenesis of type II diabetes. Obviously, insulin resistance is the initiating factor of type II diabetes, and the normal function of islet β cells is the determinant of whether type II diabetes occurs : the occurrence of insulin resistance initiates the pathogenesis of type II diabetes, but if the islet β cells can maintain its compensatory ability, type II diabetes will not occur. Once its compensatory ability decreases, type II diabetes gradually occurs. Therefore, islet β cell dysfunction is the key to the pathogenesis of type II diabetes. Exploring the harmful factors that impair β-cell function is critical for early prevention and treatment of diabetes.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Prior to conducting any trial-related activities, including those conducted to assess the subject's eligibility Informed consent of the subject;
  • Aged 18-60 years at the time of screening;
  • The diagnosis of diabetes was defined as fasting blood glucose above 7.0mmol/ L twice on different days on a normal diet

排除标准

  • HIV, hepatitis B or C ( self-reported ) or active pulmonary tuberculosis history :
  • history of malignant tumor ;
  • Severe liver dysfunction or kidney disease ( AST or ALT > 3 times the normal upper limit, or eGFR < 30ml min 1.73 m2 ) ;
  • History of severe cardiovascular and cerebrovascular diseases ( angina pectoris, myocardial infarction or stroke ) in the past 6 months :
  • history of severe gastrointestinal disease or gastrointestinal surgery in the past 12 months ;
  • There are other diseases that affect glucose and lipid metabolism : hyperthyroidism, hypothyroidism, cortex Hyperalcoholism, etc. ;
  • Secondary diseases or drugs lead to obesity, including : elevated cortisol ( such as Cushing 's syndrome ), sagging Obesity caused by body and hypothalamus injury, obesity caused by weight loss drug reduction / discontinuation, etc.
  • Drugs affecting body weight or energy intake / energy expenditure were used within 3 months before screening, including :
  • Sex steroids ( intravenous, oral or intra-articular ), tricyclic antidepressants, for psychiatric disorders

结局指标

主要结局

RBP4

时间窗: 3 years

Retinol binding protein 4

次要结局

  • HDL-C(3 years)
  • TC(3 years)
  • HbA1c(%)(3 years)
  • LDL-C(3 years)
  • BMI(3 years)
  • TT(3 years)
  • FSH(3 years)
  • AST(3 years)
  • PBG(3 years)
  • PINS(3 years)
  • UA(3 years)
  • FT(3 years)
  • HOMA-IR(3 years)
  • FINS(3 years)
  • ALT(3 years)
  • FBG(3 years)
  • TG(3 years)

研究者

发起方
Shanghai 10th People's Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Zhang Manna

Director

Shanghai 10th People's Hospital

研究点 (1)

Loading locations...

相似试验